YDO1 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Rapid Commercialization And High Gross MarginsRevenue increased sharply while gross margins remained exceptionally high, indicating strong Rezdiffra adoption and attractive product economics. This creates a substantial commercial foundation and could support operating leverage as the business scales.
Positive Equity And Substantial Asset BasePositive equity and a sizable asset base provide financial support for ongoing commercialization and pipeline activities. This balance-sheet cushion improves execution capacity over the medium term, although it does not remove the need to reduce losses and cash consumption.
Strengthened Scientific And Strategic OversightAdding a prominent biopharma R&D leader can strengthen scientific oversight, global development expertise, and governance as Madrigal expands MASH commercialization. His committee role may improve long-term pipeline and innovation decision-making.
Bears Say
Persistent UnprofitabilityDespite rapid revenue growth and high gross margins, operating expenses remain too large for the current revenue base. Continued net, EBIT, and EBITDA losses show that commercialization has not yet translated into sustainable operating profitability.
Material And Worsening Cash BurnNegative operating and free cash flow means the company is still consuming cash while scaling its commercial platform. Persistent burn could increase reliance on external funding and constrain investment flexibility until operations reach cash-flow breakeven.
Rising Leverage And Negative Capital ReturnsHigher leverage reduces financial flexibility if losses persist, while deeply negative return on equity indicates capital is being consumed rather than generating returns. This raises execution risk during the company’s commercialization and expansion phase.
Madrigal Pharmaceuticals News
YDO1 FAQ
What was Madrigal Pharmaceuticals Inc’s price range in the past 12 months?
Currently, no data Available
What is Madrigal Pharmaceuticals Inc’s market cap?
Madrigal Pharmaceuticals Inc’s market cap is CHF9.54B.
When is Madrigal Pharmaceuticals Inc’s upcoming earnings report date?
Madrigal Pharmaceuticals Inc’s upcoming earnings report date is Oct 29, 2026 which is in 21 days.
How were Madrigal Pharmaceuticals Inc’s earnings last quarter?
Madrigal Pharmaceuticals Inc released its earnings results on Jul 30, 2026. The company reported -CHF1.656 earnings per share for the quarter, beating the consensus estimate of -CHF2.228 by CHF0.572.
Is Madrigal Pharmaceuticals Inc overvalued?
According to Wall Street analysts Madrigal Pharmaceuticals Inc’s price is currently Undervalued.
Does Madrigal Pharmaceuticals Inc pay dividends?
Madrigal Pharmaceuticals Inc does not currently pay dividends.
What is Madrigal Pharmaceuticals Inc’s EPS estimate?
Madrigal Pharmaceuticals Inc’s EPS estimate is -0.7.
How many shares outstanding does Madrigal Pharmaceuticals Inc have?
Currently, no data Available
What happened to Madrigal Pharmaceuticals Inc’s price movement after its last earnings report?
Madrigal Pharmaceuticals Inc reported an EPS of -CHF1.656 in its last earnings report, beating expectations of -CHF2.228. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Madrigal Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in CH:YDO1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Madrigal Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF569.43 (― Upside)
CHF569.43 (― Upside)
Blogger Sentiment
Bullish
CH:YDO1 Sentiment 71%
Sector Average 66%
Sector Average 66%
Insider Transactions
Sold Shares
Worth CHF3.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.79%
12-Months-Change
Fundamentals
Return on Equity
-56.65%
Trailing 12-Months
Asset Growth
22.58%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
YDO1 Company Deck
YDO1 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive commercial and scientific momentum: Rezdiffra has achieved blockbuster status with rapid patient growth, a materially expanding addressable market, and an increasingly diverse pipeline (including a promising siRNA asset). These positives are balanced by elevated operating expenses, one‑time business development costs, a material gross‑to‑net discount, and near‑term non‑profitability with cash modestly reduced by strategic uses. Management emphasized durable long‑term opportunity, upcoming outcomes milestones (2027–2028), and disciplined, data‑driven pipeline advancement.View all CH:YDO1 earnings summariesYDO1 Stock 12 Month Forecast
Average Price Target
―Exelixis
―
Ionis Pharmaceuticals
―
Ascendis Pharma
―
BridgeBio Pharma
―
Roivant Sciences
―